REG-4basebio Plc: Director's Dealing

4BasebioAnnouncement

29/11/2024 12:45

29 November 2024

4basebio plc

(“4basebio” or the "Company")
 

Director’s Dealing

29 November 2024 – 4basebio PLC (AIM: 4BB) (“4basebio” or the
“Company”), which develops and commercialises the large-scale manufacture
of synthetic DNA as well as nanoparticle delivery solutions, announces that it
was informed by Dr. Heikki Lanckriet, CEO of the Company, that he acquired
ordinary shares in the Company through the market as follows: 

 Name              Number of Shares Acquired  Price per Share (p)  Shareholding Following Acquisition  Shareholding as a Percentage of Issued Share Capital  
 Heikki Lanckriet  12,000                     1,315p               1,115,288                           7.27%                                                 

The issued share capital of the Company comprises 15,477,395 ordinary shares.

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the market abuse
(amendment) (EU Exit) regulations 2019/310.

Enquiries

 4basebio PLC Dr. Heikki Lanckriet                                                      +44 (0)1223 967 943  
 Nominated Adviser Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes  +44 (0)20 7213 0880  
 Joint Corporate Broker RBC Capital Markets Rupert Walford / Kathryn Deegan             +44 (0)20 7653 4000  
 Joint Corporate Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks      +44 (0)20 7220 0500  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

 Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014                                                                                                                                              
 1   Details of the person discharging managerial responsibilities/person closely associated                                                                                                                                          
 a.  Name                                                         Dr. Heikki Lanckriet                                                                                                                                                
 2   Reason for notification                                                                                                                                                                                                          
 a.  Position/Status                                              CEO                                                                                                                                                                 
 b.  Initial notification/Amendment                               Initial Notification                                                                                                                                                
 3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor                                                                                                                    
 a.  Name                                                         4basebio plc                                                                                                                                                        
 b.  LEI                                                          213800E2DX9EAIUNCB30                                                                                                                                                
 4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted                                
 a.  Description of the financial instrument, type of instrument  Ordinary Shares                                                                                                                                                     
     			                                                                                                                                                                                                                              
     			Identification Code                                        ISIN: GB00BMCLYF79                                                                                                                                                 
 b.  Nature of the transaction                                    Acquisition of ordinary shares                                                                                                                                      
                                                                                                           Price(s) per share (p)                   Volume(s)                                                                         
     1,315p                                                                                                12,000                                                                                                                     
                                                                                                                                                        
 d.  Aggregated information * Volume                              * 12,000                                                                                                                                                            
     * Price                                                      * 1,315 pence per share                                                                                                                                             
 e.  Date of the transaction                                      28/11/2024                                                                                                                                                          
 f.  Place of the transaction                                     London Stock Exchange, AIM                                                                                                                                          



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved